Polyphyllin II Induces Protective Autophagy and Apoptosis via Inhibiting PI3K/AKT/mTOR and STAT3 Signaling in Colorectal Cancer Cells

被引:29
作者
Li, Jun-Kui [1 ,2 ]
Sun, Hai-Tao [3 ]
Jiang, Xiao-Li [1 ,2 ]
Chen, Yi-Fei [3 ]
Zhang, Zhu [1 ,2 ]
Wang, Ying [1 ,2 ]
Chen, Wen-Qing [1 ,2 ]
Zhang, Zhang [1 ,2 ]
Sze, Stephen Cho Wing [1 ,2 ]
Zhu, Pei-Li [1 ,2 ]
Yung, Ken Kin Lam [1 ,2 ]
机构
[1] Hong Kong Baptist Univ HKBU, Dept Biol, Hong Kong 999077, Peoples R China
[2] HKBU, Golden Meditech Ctr Neuro Regenerat Sci GMCNS, Hong Kong 999077, Peoples R China
[3] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Peoples R China
基金
中国国家自然科学基金;
关键词
polyphyllin II; colorectal cancer; cell cycle arrest; apoptosis; autophagy; PI3K; AKT; mTOR; STAT3; COLON-CANCER; PROLIFERATION; TARGET;
D O I
10.3390/ijms231911890
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Polyphyllin II (PPII) is a natural steroidal saponin occurring in Rhizoma Paridis. It has been demonstrated to exhibit anti-cancer activity against a variety of cancer cells. However, the anti-colorectal cancer (CRC) effects and mechanism of action of PPII are rarely reported. In the present study, we showed that PPII inhibited the proliferation of HCT116 and SW620 cells. Moreover, PPII induced G2/M-phase cell cycle arrest and apoptosis, as well as protective autophagy, in CRC cells. We found that PPII-induced autophagy was associated with the inhibition of PI3K/AKT/mTOR signaling. Western blotting results further revealed that PPII lowered the protein levels of phospho-Src (Tyr416), phospho-JAK2 (Tyr1007/1008), phospho-STAT3 (Tyr705), and STAT3-targeted molecules in CRC cells. The overactivation of STAT3 attenuated the cytotoxicity of PPII against HCT116 cells, indicating the involvement of STAT3 inhibition in the anti-CRC effects of PPII. PPII (0.5 mg/kg or 1 mg/kg, i.p. once every 3 days) suppressed HCT116 tumor growth in nude mice. In alignment with the in vitro results, PPII inhibited proliferation, induced apoptosis, and lowered the protein levels of phospho-STAT3, phospho-AKT, and phospho-mTOR in xenografts. These data suggest that PPII could be a potent therapeutic agent for the treatment of CRC.
引用
收藏
页数:16
相关论文
共 36 条
[1]   Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives [J].
Banerjee, Antara ;
Pathak, Surajit ;
Subramanium, Vimala Devi ;
Dharanivasan, G. ;
Murugesan, Ramachandran ;
Verma, Rama S. .
DRUG DISCOVERY TODAY, 2017, 22 (08) :1224-1232
[2]   Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth [J].
Corvinus, FM ;
Orth, C ;
Moriggl, R ;
Tsareva, SA ;
Wagner, S ;
Pfitzner, EB ;
Baus, D ;
Kaufmann, R ;
Huber, LA ;
Zatloukal, K ;
Beug, H ;
Öhlschäger, P ;
Schütz, A ;
Halbhuber, KJ ;
Friedrich, K .
NEOPLASIA, 2005, 7 (06) :545-555
[3]  
Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
[4]   Autophagy-dependent cell death [J].
Denton, Donna ;
Kumar, Sharad .
CELL DEATH AND DIFFERENTIATION, 2019, 26 (04) :605-616
[5]   Targeting STAT3 Signaling Pathway in Colorectal Cancer [J].
Gargalionis, Antonios N. ;
Papavassiliou, Kostas A. ;
Papavassiliou, Athanasios G. .
BIOMEDICINES, 2021, 9 (08)
[6]   Polyphyllin I suppresses proliferation and promotes apoptosis of gastric cancer cell by inhibiting stat3 phosphorylation [J].
Han, Jun ;
Kan, Jie ;
Wang, Xinguo ;
Yuan, Qingling ;
Song, Xiaoyan ;
Huang, Min ;
Wu, Hao .
TRANSLATIONAL CANCER RESEARCH, 2020, 9 (08) :4715-4725
[7]  
He Hao, 2015, Asian Pac J Cancer Prev, V16, P1169
[8]   mTOR: a pharmacologic target for autophagy regulation [J].
Kim, Young Chul ;
Guan, Kun-Liang .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (01) :25-32
[9]   STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment [J].
Laudisi, Federica ;
Cherubini, Fabio ;
Monteleone, Giovanni ;
Stolfi, Carmine .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (06)
[10]   Highlighted STAT3 as a potential drug target for cancer therapy [J].
Lee, Haeri ;
Jeong, Ae Jin ;
Ye, Sang-Kyu .
BMB REPORTS, 2019, 52 (07) :415-423